PT - JOURNAL ARTICLE AU - Anzar, Irantzu AU - Malone, Brandon AU - Samarakoon, Pubudu AU - Vardaxis, Ioannis AU - Simovski, Boris AU - Fontenelle, Hugues AU - Meza-Zepeda, Leonardo A AU - Stratford, Richard AU - Keung, Emily Z AU - Burgess, Melissa AU - Tawbi, Hussein A. AU - Myklebost, Ola AU - Clancy, Trevor TI - The interplay between neoantigens and immune cells in sarcomas treated with checkpoint inhibition AID - 10.1101/2023.05.20.23290277 DP - 2023 Jan 01 TA - medRxiv PG - 2023.05.20.23290277 4099 - http://medrxiv.org/content/early/2023/05/23/2023.05.20.23290277.short 4100 - http://medrxiv.org/content/early/2023/05/23/2023.05.20.23290277.full AB - Sarcomas are comprised of diverse bone and connective tissue tumors with few effective therapeutic options for locally advanced unresectable and/or metastatic disease. Recent advances in immunotherapy, in particular immune checkpoint inhibition (ICI), have shown promising outcomes in several cancer indications. Unfortunately, ICI therapy has provided only modest clinical responses and seems moderately effective in a subset of the diverse subtypes. To explore the immune parameters governing ICI therapy resistance or immune escape, we performed whole exome sequencing (WES) on tumors and their matched normal blood, in addition to RNA-seq from tumors of 31 sarcoma patients treated with pembrolizumab. We used advanced computational methods to investigate key immune properties, such as neoantigens and immune cell composition in the tumor microenvironment (TME). A multifactorial analysis suggested that expression of high quality neoantigens in the context of specific immune cells in the TME are key prognostic markers of progression-free survival (PFS). The presence of several types of immune cells, including T cells, B cells and macrophages, in the TME were associated with improved PFS. Importantly, we also found the presence of both CD8+ T cells and neoantigens together was associated with improved survival compared to the presence of CD8+ T cells or neoantigens alone. Interestingly, this trend was not identified with the combined presence of CD8+ T cells and TMB; suggesting that a combined CD8+ T cell and neoantigen effect on PFS was important. The outcome of this study may inform future trials that may lead to improved outcomes for sarcoma patients treated with ICI.Competing Interest StatementIA, BM, PS, IV, BS, HF, RS, and TC are employees of the commercial company NEC OncoImmunity.Funding StatementThis work was supported by grant MISP # 53061 from Merck and from the Norwegian Research Council.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The import and analysis of the available samples to Norway was approved by the Committee for Medical Ethics in Southeastern Norway #17866I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe NGS data are stored at the "Services for sensitive data" of the University of Oslo Computing Centre, providing strong protection but also controlled access for approved users in compliance with the patient consents. Access may be obtained by contacting OM or LAMZ.